Literature DB >> 6412929

Topical minoxidil in the treatment of alopecia areata.

D A Fenton, J D Wilkinson.   

Abstract

A modified double blind crossover study was performed to assess the effect of 1% topical minoxidil as compared with placebo in 30 patients with alopecia areata and alopecia totalis. The active preparation produced a highly significant incidence of hair regrowth. A cosmetically acceptable response was noted in 16 patients. No side effects were seen. The study confirmed that topical minoxidil will induce new hair growth in alopecia areata but that it is less likely to do so in more severe and extensive disease. Furthermore, patients with alopecia universalis and totalis may not respond at all. Nevertheless, as compared with other drugs minoxidil applied topically is relatively non-toxic, is easy to use, and has no systemic or local side effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6412929      PMCID: PMC1549582          DOI: 10.1136/bmj.287.6398.1015

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  10 in total

1.  Minoxidil treatment of severe hypertension.

Authors:  J R Ryan; A K Jain; F G McMahon
Journal:  Curr Ther Res Clin Exp       Date:  1975-01

Review 2.  The pharmacologic basis of antihypertensive therapy: The role of vasodilator drugs.

Authors:  C A Chidsey; T B Gottlieb
Journal:  Prog Cardiovasc Dis       Date:  1974 Sep-Oct       Impact factor: 8.194

3.  Topical minoxidil in alopecia areata.

Authors:  V C Weiss; D P West; C E Mueller
Journal:  J Am Acad Dermatol       Date:  1981-08       Impact factor: 11.527

4.  Reversal of baldness in patient receiving minoxidil for hypertension.

Authors:  A R Zappacosta
Journal:  N Engl J Med       Date:  1980-12-18       Impact factor: 91.245

5.  Minoxidil in resistant hypertension.

Authors:  H J Dargie; C T Dollery; J Daniel
Journal:  Lancet       Date:  1977-09-10       Impact factor: 79.321

6.  Hypertrichosis due to diazoxide.

Authors:  J L Burton; W H Schutt; I W Caldwell
Journal:  Br J Dermatol       Date:  1975-12       Impact factor: 9.302

Review 7.  Pharmacology and pharmacokinetics of minoxidil.

Authors:  D T Lowenthal; M B Affrime
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

8.  Minoxidil-induced hypertrichosis: treatment with calcium thioglycolate depilatory.

Authors:  R N Earhart; J Ball; D D Nuss; J L Aeling
Journal:  South Med J       Date:  1977-04       Impact factor: 0.954

9.  Hypertrichosis due to minoxidil.

Authors:  J L Burton; A Marshall
Journal:  Br J Dermatol       Date:  1979-11       Impact factor: 9.302

10.  Alopecia areata treated with tropical minoxidil.

Authors:  D A Fenton; J D Wilkinson
Journal:  J R Soc Med       Date:  1982-12       Impact factor: 18.000

  10 in total
  7 in total

Review 1.  Topical minoxidil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

2.  Unravelling the pathophysiology of male pattern baldness.

Authors:  B D Herring
Journal:  J Natl Med Assoc       Date:  1985-02       Impact factor: 1.798

Review 3.  Alopecia Areata: An Update on Treatment Options for Children.

Authors:  Lauren Peloquin; Leslie Castelo-Soccio
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

Review 4.  Beneficial Extracardiac Effects of Cardiovascular Medications.

Authors:  Asra K Butt; Jay Patel; Hamid Shirwany; Qasim Mirza; Jonathan Hoover; Rami N Khouzam
Journal:  Curr Cardiol Rev       Date:  2022

5.  Management of alopecia areata.

Authors:  M J Harries; J Sun; R Paus; L E King
Journal:  BMJ       Date:  2010-07-23

6.  Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase.

Authors:  Soohwan Yum; Seongkeun Jeong; Dohoon Kim; Sunyoung Lee; Wooseong Kim; Jin-Wook Yoo; Jung-Ae Kim; Oh Sang Kwon; Dae-Duk Kim; Do Sik Min; Yunjin Jung
Journal:  Int J Mol Sci       Date:  2017-12-25       Impact factor: 5.923

7.  Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity.

Authors:  Conor McClenaghan; Yan Huang; Zihan Yan; Theresa M Harter; Carmen M Halabi; Rod Chalk; Attila Kovacs; Gijs van Haaften; Maria S Remedi; Colin G Nichols
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.